Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


Antisense oligonucleotides for atherosclerotic disease

Novel RNA-targeting antisense therapy is shown to reduce lipoprotein(a) levels in 286 patients with existing atherosclerotic disease by upwards of 80% in a phase 2 clinical trial.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: An oligonucleotide for atherosclerosis.


  1. Tsimikas, S. et al. J. Am. Coll. Cardiol. 71, 177–192 (2018).

    Article  CAS  Google Scholar 

  2. Tsimikas, S. et al. N. Engl. J. Med. 382, 244–255 (2020).

    Article  CAS  Google Scholar 

  3. Paré, G. et al. Circulation 139, 1472–1482 (2019).

    Article  Google Scholar 

  4. Clarke, R. et al. N. Engl. J. Med. 361, 2518–2528 (2009).

    Article  CAS  Google Scholar 

  5. Burgess, S. et al. JAMA Cardiol. 3, 619–627 (2018).

    Article  Google Scholar 

  6. Thanassoulis, G. et al. N. Engl. J. Med. 368, 503–512 (2013).

    Article  CAS  Google Scholar 

  7. de Oliveira Sá, M. P. B. et al. Curr. Atheroscler. Rep. 22, 2 (2020).

    Article  Google Scholar 

  8. Boffa, M. B. & Koschinsky, M. L. Nat. Rev. Cardiol. 16, 305–318 (2019).

    Article  Google Scholar 

  9. Willeit, P. et al. Lancet 392, 1311–1320 (2018).

    Article  CAS  Google Scholar 

  10. Wilson, D. P. et al. J. Clin. Lipidol. 13, 374–392 (2019).

    Article  Google Scholar 

  11. Varvel, S., McConnell, J. P. & Tsimikas, S. Arterioscler. Thromb. Vasc. Biol. 36, 2239–2245 (2016).

    Article  CAS  Google Scholar 

  12. O’Donoghue, M. L. et al. Circulation 139, 1483–1492 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Daniel J. Rader.

Ethics declarations

Competing interests

D. J. R. serves on the Scientific Advisory Board for Alnylam, which makes small interfering RNA therapeutics, and for Novartis, which has licensed AKCEA-APO(a)-LRx.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bajaj, A., Rader, D.J. Antisense oligonucleotides for atherosclerotic disease. Nat Med 26, 471–472 (2020).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing